专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20060040999A1 CETP inhibitors 有权
标题翻译： CETP抑制剂
公开(公告)号：US20060040999A1
公开(公告)日：2006-02-23
申请号：US11173295
申请日：2005-07-01
申请人： Amjad Ali , Joann Napolitano , Qiaolin Deng , Zhijian Lu , Peter Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi , Cameron Smith , Julianne Hunt , Adrian Dowst , Yi-Heng Chen , Hong Li
发明人： Amjad Ali , Joann Napolitano , Qiaolin Deng , Zhijian Lu , Peter Sinclair , Gayle Taylor , Christopher Thompson , Nazia Quraishi , Cameron Smith , Julianne Hunt , Adrian Dowst , Yi-Heng Chen , Hong Li
IPC分类号： A61K31/421 , C07D263/16
CPC分类号： C07F7/10 , A61K31/4015 , A61K31/4166 , A61K31/4168 , A61K31/421 , A61K31/422 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07D207/26 , C07D207/27 , C07D233/32 , C07D233/38 , C07D233/50 , C07D233/52 , C07D263/04 , C07D263/20 , C07D263/22 , C07D263/24 , C07D263/26 , C07D285/06 , C07D285/10 , C07D401/04 , C07D413/04 , C07D413/06 , C07D413/10 , C07D417/04 , C07D417/10
摘要： Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
摘要翻译：具有式I结构的化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于升高HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。在式I化合物中，B或 R 2是具有邻芳基，杂环，苯并杂环或苯并环烷基取代基的苯基，并且在5元环上的另一个位置具有直接连接的芳族，杂环，环烷基，苯并杂环或苯并环烷基取代基通过-CH 2 - 2连接到环上或连接到环上。

22. 发明授权

US09969724B2 Factor IXa inhibitors 有权
公开(公告)号：US09969724B2
公开(公告)日：2018-05-15
申请号：US15303310
申请日：2015-04-10
申请人： Isao Sakurada , Tomokazu Hirabayashi , Yoshitaka Maeda , Hiroshi Nagasue , Takashi Mizuno , Jiayi Xu , Ting Zhang , Cameron Smith , Dann Parker
发明人： Isao Sakurada , Tomokazu Hirabayashi , Yoshitaka Maeda , Hiroshi Nagasue , Takashi Mizuno , Jiayi Xu , Ting Zhang , Cameron Smith , Dann Parker
IPC分类号： A61K31/506 , C07D413/14 , C07D471/04 , C07D413/04 , C07D417/14 , C07D498/04 , C07D519/00 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/52 , A61K45/06
CPC分类号： C07D413/14 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K45/06 , C07D413/04 , C07D417/14 , C07D471/04 , C07D498/04 , C07D519/00
摘要： In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

23. 发明授权

US09221834B2 Cyclic amine substituted oxazolidinone CETP inhibitor 有权
标题翻译：环胺取代的恶唑烷酮CETP抑制剂
公开(公告)号：US09221834B2
公开(公告)日：2015-12-29
申请号：US13881896
申请日：2011-10-25
申请人： Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
发明人： Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
IPC分类号： A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/4545 , A61K31/497 , A61K31/444 , C07D491/08 , C07D417/14 , C07D413/14 , A61K31/42 , A61K45/06 , C07D413/06
CPC分类号： C07D491/08 , A61K31/42 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D413/06 , C07D413/14 , C07D417/14 , A61K2300/00
摘要： Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
摘要翻译：具有式I结构的化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于培养HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。在式I的化合物中，A3是取代的苯基或茚满基。式（I）。

24. 发明授权

US09120758B2 Neprilysin inhibitors 有权
公开(公告)号：US09120758B2
公开(公告)日：2015-09-01
申请号：US14024974
申请日：2013-09-12
申请人： Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
发明人： Cameron Smith , Melissa Fleury , Roland Gendron , Ryan Hudson , Adam D. Hughes
IPC分类号： C07D231/14 , C07D401/06 , C07D261/18 , C07D249/10 , C07D471/04 , C07D257/04 , C07D263/34 , C07C281/02 , C07D231/20 , C07D231/22 , C07D231/40 , C07D237/24 , C07D239/36 , C07D239/54 , C07D249/04 , C07D249/12 , C07D249/18 , C07D263/38 , C07D277/56 , C07D401/04 , C07D403/04 , C07D403/06 , C07D413/04 , C07D239/28 , C07D239/34 , C07D239/52
CPC分类号： C07D471/04 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/422 , A61K31/426 , A61K31/437 , A61K31/4439 , A61K31/454 , A61K31/497 , A61K31/50 , A61K31/505 , A61K31/5377 , C07C281/02 , C07D231/14 , C07D231/20 , C07D231/22 , C07D231/40 , C07D237/14 , C07D237/24 , C07D239/28 , C07D239/34 , C07D239/36 , C07D239/52 , C07D239/54 , C07D249/04 , C07D249/10 , C07D249/12 , C07D249/18 , C07D257/04 , C07D261/12 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/38 , C07D277/34 , C07D277/56 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D413/04 , Y02P20/55
摘要： In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

25. 发明申请

US20130331372A1 Cyclic Amine Substituted Oxazolidinone CETP Inhibitor 有权
标题翻译：环胺取代的恶唑烷酮CETP抑制剂
公开(公告)号：US20130331372A1
公开(公告)日：2013-12-12
申请号：US13881896
申请日：2011-10-25
申请人： Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
发明人： Zhijian Lu , Yi-Heng Chen , Cameron Smith , Hong Li , Christopher F. Thompson , Julianne Hunt , Florida Kallashi , Ramzi Sweis , Peter Sinclair , Samantha E. Adamson , Guizhen Dong , Debra L. Ondeyka , Xiaoxia Qian , Wanying Sun , Petr Vachal , Kake Zhao
IPC分类号： C07D491/08 , A61K31/5377 , A61K31/4545 , A61K31/444 , A61K31/497 , C07D417/14 , C07D413/14 , A61K45/06 , A61K31/4439 , A61K31/506
CPC分类号： C07D491/08 , A61K31/42 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D413/06 , C07D413/14 , C07D417/14 , A61K2300/00
摘要： Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substituted phenyl group or indanyl group. Formula (I).
摘要翻译：具有式I结构的化合物，包括化合物的药学上可接受的盐，是CETP抑制剂，可用于培养HDL-胆固醇，降低LDL-胆固醇，以及用于治疗或预防动脉粥样硬化。在式I的化合物中，A3是取代的苯基或茚满基。式（I）。

26. 发明申请

US20130281489A1 QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS 有权
标题翻译：季铵化合物作为MUSCARINIC受体拮抗剂有用
公开(公告)号：US20130281489A1
公开(公告)日：2013-10-24
申请号：US13921396
申请日：2013-06-19
申请人： Craig Husfeld , YuHua Ji , Rick Lee , Li Li , YongQi Mu , Cameron Smith , Johnny Uy
发明人： Craig Husfeld , YuHua Ji , Rick Lee , Li Li , YongQi Mu , Cameron Smith , Johnny Uy
IPC分类号： C07D405/06
CPC分类号： C07D409/14 , C07D205/04 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12
摘要： The invention provides compounds of the formula: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
摘要翻译：本发明提供下式的化合物：盐或两性离子形式或其药学上可接受的盐，其中R1-6，a，Z和Q如说明书中所定义。这些化合物是毒蕈碱受体拮抗剂。本发明还提供含有这些化合物的药物组合物，制备这些化合物的方法和使用这些化合物例如治疗慢性阻塞性肺疾病和哮喘等肺疾病的方法。

27. 发明授权

US08354454B2 Prodrugs of oxazolidinone CETP inhibitors 有权
标题翻译：恶唑烷酮CETP抑制剂的前药
公开(公告)号：US08354454B2
公开(公告)日：2013-01-15
申请号：US13121972
申请日：2009-09-21
申请人： Sander G. Mills , Amjad Ali , Cameron Smith
发明人： Sander G. Mills , Amjad Ali , Cameron Smith
IPC分类号： A61K31/135 , C07C211/03 , C07C211/54
CPC分类号： A61K31/42 , C07C219/22 , C07C219/28 , C07C229/36 , C07C329/06 , C07C2601/14 , C07F9/091 , C07F9/093 , C07F9/094
摘要： The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.
摘要翻译：式I的化合物是具有中心恶唑烷酮环的CETP抑制剂的前药。通过消除HX，在给予患者后，化合物环化形成恶唑烷酮环。

28. 发明申请

US20120277250A1 AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS 有权
标题翻译：含有AMIDINE的化合物作为MUSCARINIC受体拮抗剂有用
公开(公告)号：US20120277250A1
公开(公告)日：2012-11-01
申请号：US13546583
申请日：2012-07-11
申请人： YuHua Ji , Craig HUSFELD , YongQi MU , Cameron Smith
发明人： YuHua Ji , Craig HUSFELD , YongQi MU , Cameron Smith
IPC分类号： A61K31/495 , C07D211/58 , A61P11/06 , C07D207/12 , A61K31/40 , A61P11/00 , C07D295/192 , A61K31/4468
CPC分类号： C07D295/195 , C07D207/12 , C07D211/58 , C07D409/12
摘要： The invention relates to compounds of formula I: or a pharmaceutically acceptable salt thereof, where R1-3, R5, R7, a, b, Q, X, X′, X″, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
摘要翻译：本发明涉及式I化合物或其药学上可接受的盐，其中R1-3，R5，R7，a，b，Q，X，X'，X“，Y，Z和Ar定义如规范。这些化合物是毒蕈碱受体拮抗剂。本发明还涉及含有这种化合物的药物组合物，制备这些化合物的方法和使用这些化合物例如治疗慢性阻塞性肺疾病和哮喘等肺病的方法。

29. 发明授权

US08202891B2 Quaternary ammonium compounds useful as muscarinic receptor antagonists 有权
标题翻译：可用作毒蕈碱受体拮抗剂的季铵化合物
公开(公告)号：US08202891B2
公开(公告)日：2012-06-19
申请号：US12148887
申请日：2008-04-23
申请人： Craig Husfeld , YuHua Ji , Rick Lee , Li Li , YongQi Mu , Cameron Smith , Johnny Uy
发明人： Craig Husfeld , YuHua Ji , Rick Lee , Li Li , YongQi Mu , Cameron Smith , Johnny Uy
IPC分类号： A61K31/4468 , C07D211/58
CPC分类号： C07D409/14 , C07D205/04 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12
摘要： The invention provides compounds of the formula: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a, Z and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
摘要翻译：本发明提供下式的化合物：盐或两性离子形式或其药学上可接受的盐，其中R1-6，a，Z和Q如说明书中所定义。这些化合物是毒蕈碱受体拮抗剂。本发明还提供含有这些化合物的药物组合物，制备这些化合物的方法和使用这些化合物例如治疗慢性阻塞性肺疾病和哮喘等肺疾病的方法。

30. 发明授权

US08129855B1 Portable turbine systems 有权
标题翻译：便携式涡轮机系统
公开(公告)号：US08129855B1
公开(公告)日：2012-03-06
申请号：US12315456
申请日：2008-12-02
申请人： Lucas Tong , Cameron Smith
发明人： Lucas Tong , Cameron Smith
IPC分类号： F03B13/00
CPC分类号： F03B17/063 , F05B2240/93 , Y02E10/28
摘要： Novel apparatus and techniques for harnessing wind and/or moving-liquid energy using one or more portable turbine systems are disclosed. One embodiment includes a portable stream turbine system having a hub with many paddles, held by an axle in a housing. The system further includes a disk fixed to the hub and extended out of the housing to be also fixed to a gear structure, which is connected to a generator. The output of the generator can be connected to electronics to perform different functions. Another embodiment includes a number of portable turbine systems removably attached together to form an array. In one example, the number of portable turbine systems in an array can be adjustable, depending on needs. The different embodiments regarding a stream turbine system can further include a floatation mechanism to keep the different embodiments afloat or partially afloat in a fluid. The different embodiments regarding a stream turbine system or an array of stream turbine systems can also include a drifting prevention mechanism to prevent the embodiments from being drifted away, and to substantially maintain the orientation of the embodiments in a fluid.
摘要翻译：公开了使用一个或多个便携式涡轮机系统来利用风和/或移动液体能量的新颖的装置和技术。一个实施例包括具有许多桨叶的轮毂的便携式流涡轮机系统，其通过轴在壳体中保持。该系统还包括固定到轮毂并延伸出壳体的盘，该盘也固定到连接到发电机的齿轮结构。发电机的输出可以连接到电子设备，以执行不同的功能。另一实施例包括多个便携式涡轮机系统，其可拆卸地连接在一起以形成阵列。在一个示例中，根据需要，阵列中的便携式涡轮机系统的数量可以是可调节的。关于流涡轮机系统的不同实施例可以进一步包括浮动机构以将不同的实施例保持在浮动或部分浮动在流体中。关于流涡轮机系统或流涡轮机系统阵列的不同实施例还可以包括防止这些实施例被漂移的漂移防止机构，并且基本保持实施例在流体中的取向。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式